NCT01335451CompletedPhase 1
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Oral Administration of Single and Multiple Ascending Doses in Healthy Young and Elderly J
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- To assess the safety and tolerability of AZD5213 by assessment of adverse event, vital signs, laboratory parameters and electrocardiograms (ECGs).
Study Overview
Brief Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of AZD5213 in healthy young and elderly Japanese subjects
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 20 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Provision of signed and dated, written informed consent prior to any study specific procedures
- •Japanese healthy male subjects aged 20 to 45 years (young) and male and female subjects aged 65 to 80 years (elderly)
- •Male subjects should be willing to use barrier contraception ie, condoms, from the first day of dosing until 3 months after the last dose of investigational product
- •Have a body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 45 kg and no more than 100 kg
- •Clinically normal physical findings, supine BP, pulse rate, ECG and laboratory assessments in relation to age, as judged by the investigator(s)
Exclusion Criteria
- •History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
- •History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
- •History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, and personality disorder including borderline according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders
- •History of psychotic disorder among first degree relatives.
- •History of use of antipsychotic, antidepressant or anxiolytic drugs, prescribed as well as non-prescribed use.
Arms & Interventions
Active
Experimental
Each cohort will have 6 subjects that will receive AZD5213
Intervention: AZD5213 (Drug)
Placebo
Placebo Comparator
Each cohort will have 2 subjects that will receive placebo
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
To assess the safety and tolerability of AZD5213 by assessment of adverse event, vital signs, laboratory parameters and electrocardiograms (ECGs).
Time Frame: Range of Days 1-12
Secondary Outcomes
- To assess the PK of AZD5213 after a single and multiple doses by assessment of CL/F.(Range of Days 1-12)
- To assess the PK of AZD5213 after a single and multiple doses by assessment of Cmax.(Range of Days 1-12)
- To assess the PK of AZD5213 after a single and multiple doses by assessment of t1/2.(Range of Days 1-12)
- To assess the PK of AZD5213 after a single and multiple doses by assessment of AUC.(Range of Days 1-12)
- To assess the PK of AZD5213 after a single and multiple doses by assessment of fe.(Range of Days 1-12)
- To assess the PK of AZD5213 after a single and multiple doses by assessment of CLR.(Range of Days 1-12)
- To assess the PK of AZD5213 after a single and multiple doses by assessment of tmax.(Range of Days 1-12)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female SubjectsTolerabilityNCT01121302AstraZeneca88
Completed
Phase 1
Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female SubjectsHealthyNCT01171105AstraZeneca73
Terminated
Phase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.Dilated CardiomyopathyNCT06381466AstraZeneca84
Completed
Phase 1
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal ImpairmentRenal ImpairmentNCT06661733AstraZeneca16
Completed
Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy VolunteersHealthy ParticipantsNCT04994106AstraZeneca98